Eltrombopag
20 interactions 1 explained in plain EnglishEltrombopag is used to increase the number of platelets (cells that help the blood clot) to decrease the risk of bleeding in adults and children 1 year of age and older who have chronic immune thrombocytopenia (ITP; an ongoing condition that may cause unusual bruising or bleeding due to an abnormally low number of plat… Read the full Eltrombopag drug information page →
Sources: FDA prescribing information (Structured Product Labeling), the published literature cited in each entry, DDInter 2.0 (a major open-access drug-interaction database), and legacy DrugBank interaction data distributed by the NIH's RxNav service (decommissioned in 2024) — analyzed and reviewed by our pharmacist team. How we build this library →
Major
Eltrombopag Simvastatin Flolipid Explained Increased risk of simvastatin toxicity, including an increased risk of myopathy or rhabdomyolysis Details Eltrombopag Alpelisib Piqray Increased alpelisib exposure and an increased risk of alpelisib-related adverse effects and toxicity Details Eltrombopag Atogepant Qulipta Increased atogepant exposure Details Eltrombopag Atorvastatin Atorvaliq Increased OATP1B1 substrates exposure and an increased risk of OATP1B1 substrates-related adverse reactions Details Eltrombopag Axitinib Inlyta Increased OATP1B1 substrates exposure and an increased risk of OATP1B1 substrates-related adverse reactions Details Eltrombopag Docetaxel Beizray Increased OATP1B1 substrates exposure and an increased risk of OATP1B1 substrates-related adverse reactions Details Eltrombopag Docetaxel Injection Beizray Increased OATP1B1 substrates exposure and an increased risk of OATP1B1 substrates-related adverse reactions Details Eltrombopag Eluxadoline Viberzi Increased eluxadoline exposure Details Eltrombopag Exemestane Aromasin Increased OATP1B1 substrates exposure and an increased risk of OATP1B1 substrates-related adverse reactions Details Eltrombopag Ezetimibe Zetia Increased ezetimibe exposure and an increased risk of ezetimibe-related adverse reactions Details Eltrombopag Fexofenadine Allegra Increased OATP1B1 substrates exposure and an increased risk of OATP1B1 substrates-related adverse reactions Details Eltrombopag Fluvastatin Lescol Increased OATP1B1 substrates exposure and an increased risk of OATP1B1 substrates-related adverse reactions Details Eltrombopag Irinotecan Camptosar Increased irinotecan exposure and an increased risk of irinotecan-related adverse reactions Details Eltrombopag Irinotecan Injection Camptosar Increased irinotecan exposure and an increased risk of irinotecan-related adverse reactions Details Eltrombopag Letermovir Injection Prevymis Increased OATP1B1 substrates exposure and an increased risk of OATP1B1 substrates-related adverse reactions Details Eltrombopag Lovastatin Altocor® Increased OATP1B1 substrates exposure and an increased risk of OATP1B1 substrates-related adverse reactions Details Eltrombopag Methotrexate Jylamvo Increased methotrexate exposure and an increased risk of methotrexate-related adverse reactions Details Eltrombopag Methotrexate Injection Abitrexate® Increased methotrexate exposure and an increased risk of methotrexate-related adverse reactions Details Eltrombopag Mitoxantrone Injection Novantrone® Increased mitoXANTRONE exposure and an increased risk of mitoXANTRONE-related adverse reactions Details Eltrombopag Nateglinide Starlix® Increased OATP1B1 substrates exposure and an increased risk of OATP1B1 substrates-related adverse reactions DetailsNo interactions on this page match that filter — try the next page or clear the filter.
Check another drug
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist